Market Summary

Introduction

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology                  
2    Executive Summary
3    Global Generic Drugs Market Overview 

    3.1    Global Generic Drugs Market Historical Value (2017-2023) 
    3.2    Global Generic Drugs Market Forecast Value (2024-2032)
4    Global Generic  Drugs Market Landscape*
    4.1    Global Generic Drugs: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Generic Drugs: Product Landscape
        4.2.1    Analysis by Therapy Area
        4.2.2    Analysis by Route of Administration
        4.2.3    Analysis by Distribution Channels
5    Global Generic Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Global Generic Drugs Market Segmentation (2017-2032)
    6.1    Global Generic Drugs Market (2017-2032) by Therapy Area
        6.1.1    Market Overview
        6.1.2    Cardiovascular
        6.1.3    Dermatology
        6.1.4    Respiratory
        6.1.5    Oncology
        6.1.6    Rheumatology 
        6.1.7    Others
    6.2    Global Generic Drugs Market (2017-2032) by Route of Administration
        6.2.1    Market Overview
        6.2.2    Oral
        6.2.3    Injectables
        6.2.4    Dermal/Topical
        6.2.5    Inhalers
        6.2.6    Others
    6.3    Global Generic Drugs Market (2017-2032) by Distribution Channels
        6.3.1    Market Overview
        6.3.2    Hospital Pharmacy
        6.3.3    Retail Pharmacy
        6.3.4    Online Pharmacy
        6.3.5    Others
    6.4    Global Generic Drugs Market (2017-2032) by Region
        6.4.1    Market Overview
        6.4.2    North America
        6.4.3    Europe 
        6.4.4    Asia Pacific
        6.4.5    Latin America
        6.4.6    Middle East and Africa
7    North America Generic Drugs Market (2017-2032)
    7.1    North America Generic Drugs Market (2017-2032) by Therapy Area
        7.1.1    Market Overview
        7.1.2    Cardiovascular
        7.1.3    Dermatology
        7.1.4    Respiratory
        7.1.5    Oncology
        7.1.6    Rheumatology 
        7.1.7    Others
    7.2    North America Generic Drugs Market (2017-2032) by Route of Administration
        7.2.1    Market Overview
        7.2.2    Oral
        7.2.3    Injectables
        7.2.4    Dermal/Topical
        7.2.5    Inhalers
        7.2.6    Others
    7.3    North America Generic Drugs Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Generic Drugs Market (2017-2032)
    8.1    Europe Generic Drugs Market (2017-2032) by Therapy Area
        8.1.1    Market Overview
        8.1.2    Cardiovascular
        8.1.3    Dermatology
        8.1.4    Respiratory
        8.1.5    Oncology
        8.1.6    Rheumatology 
        8.1.7    Others
    8.2    Europe Generic Drugs Market (2017-2032) by Route of Administration
        8.2.1    Market Overview
        8.2.2    Oral
        8.2.3    Injectables
        8.2.4    Dermal/Topical
        8.2.5    Inhalers
        8.2.6    Others
    8.3    Europe Generic Drugs Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Generic Drugs Market (2017-2032)
    9.1    Asia Pacific Generic Drugs Market (2017-2032) by Therapy Area
        9.1.1    Market Overview
        9.1.2    Cardiovascular
        9.1.3    Dermatology
        9.1.4    Respiratory
        9.1.5    Oncology
        9.1.6    Rheumatology 
        9.1.7    Others
    9.2    Asia Pacific Generic Drugs Market (2017-2032) by Route of Administration
        9.2.1    Market Overview
        9.2.2    Oral
        9.2.3    Injectables
        9.2.4    Dermal/Topical
        9.2.5    Inhalers
        9.2.6    Others
    9.3    Asia Pacific Generic Drugs Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    ASEAN
        9.3.5    Australia
        9.3.6    Others
10    Latin America Generic Drugs Market (2017-2032)
    10.1    Latin America Generic Drugs Market (2017-2032) by Therapy Area
        10.1.1    Market Overview
        10.1.2    Cardiovascular
        10.1.3    Dermatology
        10.1.4    Respiratory
        10.1.5    Oncology
        10.1.6    Rheumatology 
        10.1.7    Others
    10.2    Latin America Generic Drugs Market (2017-2032) by Route of Administration
        10.2.1    Market Overview
        10.2.2    Oral
        10.2.3    Injectables
        10.2.4    Dermal/Topical
        10.2.5    Inhalers
        10.2.6    Others
    10.3    Latin America Generic Drugs Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East  and Africa Generic Drugs Market (2017-2032)
    11.1    Middle East and Africa Generic Drugs Market (2017-2032) by Therapy Area
        11.1.1    Market Overview
        11.1.2    Cardiovascular
        11.1.3    Dermatology
        11.1.4    Respiratory
        11.1.5    Oncology
        11.1.6    Rheumatology 
        11.1.7    Others
    11.2    Middle East and Africa Generic Drugs Market (2017-2032) by Route of Administration
        11.2.1    Market Overview
        11.2.2    Oral
        11.2.3    Injectables
        11.2.4    Dermal/Topical
        11.2.5    Inhalers
        11.2.6    Others
    11.3    Middle East and Africa Generic Drugs Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory Framework
    12.1     Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent Analysis
    13.1     Analysis by Type of Patent
    13.2     Analysis by Publication year
    13.3     Analysis by Issuing Authority
    13.4     Analysis by Patent Age
    13.5     Analysis by CPC Analysis
    13.6     Analysis by Patent Valuation 
    13.7     Analysis by Key Players
14    Grants Analysis
    14.1     Analysis by Year
    14.2     Analysis by Amount Awarded
    14.3     Analysis by Issuing Authority
    14.4     Analysis by Grant Housing Material 
    14.5     Analysis by Funding Institute
    14.6     Analysis by Departments
    14.7     Analysis by Recipient Organization 
15    Funding and Investment Analysis
    15.1     Analysis by Funding Instances
    15.2     Analysis by Type of Funding
    15.3     Analysis by Funding Amount
    15.4     Analysis by Leading Players
    15.5     Analysis by Leading Investors
    15.6     Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1     Analysis by Partnership Instances
    16.2     Analysis by Type of Partnership
    16.3     Analysis by Leading Players
    16.4     Analysis by Geography
17    Supplier Landscape
    17.1    Market Share by Top 5 Companies 
    17.2    Teva Pharmaceutical Industries Ltd
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications 
    17.3    Viatris Inc. 
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications 
    17.4    Sun Pharmaceutical Industries Ltd
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications 
    17.5    Lupin
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications 
    17.6    AstraZeneca
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications 
    17.7    Almirall, S.A 
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications 
    17.8    Takeda Pharmaceutical Company Limited
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications 
    17.9    GSK plc
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications 
    17.10    Bausch + Lomb
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications 
    17.11    Novartis AG
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications 
    17.12    Sanofi
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications 
    17.13    Pfizer Inc.
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications 
    17.14    Fresenius SE & Co. KGaA
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications 
    17.15    Hikma Pharmaceuticals PLC
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications 
    17.16    Aurobindo Pharma
        17.16.1    Financial Analysis
        17.16.2    Product Portfolio
        17.16.3    Demographic Reach and Achievements
        17.16.4    Mergers and Acquisitions
        17.16.5    Certifications
18    Global Generic Drugs Market – Distribution Model (Additional Insight)
    18.1     Overview 
    18.2     Potential Distributors 
    18.3     Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1     Very Small Companies
    20.2     Small Companies
    20.3     Mid-Sized Companies
    20.4     Large Companies
    20.5     Very Large Companies
21    Payment  Methods (Additional Insight)
    21.1     Government Funded
    21.2     Private Insurance
    21.3     Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*Additional insights provided are customizable as per client requirements.

*The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124